Incidence of mutations in mCRC patients
ESMO guidelines recommend that 'BRAF mutation status should be assessed simultaneously with the evaluation of RAS, for prognostic assessment and for the option of treatment with cetuximab-encorafenib'6
approximately
50%
RAS
mutations7
up to
12%
BRAF
mutations7
Visit www.testmCRCmutations.com to learn more
Why test?6
- Adhere to ESMO guideline recommendations, which base the use of cytotoxics and biologicals on molecular profile
- Gain a deeper knowledge of the impact and clinical relevance of mutations
- Promote enrolment of patients into clinical trials with new targeted approaches
- Improve outcomes for patients with mCRC
Molecular heterogeneity of colorectal cancer is substantial
The MAPK pathway is the most frequently dysregulated signalling pathway linked to various cancers, such as colorectal cancer. Key drivers for the aberrant MAPK signalling are mutations in the downstream pathway components RAS or BRAF.1,2
Created from Refs. 1, 2
EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase.
Patients with mCRC with RAS- or BRAF-mutated tumours may have poorer outcomes than those with wild-type tumours
RAS- and, to a greater extent, BRAF-mutated tumours may be associated with a poorer prognosis than RAS and BRAF wild-type tumours, based on retrospective analyses of clinical trial data3-5
Overall survival according to molecular subgroups in 357 patients with mCRC receiving first-line treatment3
Adapted from the TRIBE study: Ref. 3
According to the study protocol, the mutation status of KRAS codons 12, 13, and 61 and of BRAF codon 600 was assessed
ND/ONC/11/23/0001